Alkem Laboratories Ltd

Alkem Laboratories Ltd

₹ 5,409 0.04%
26 Dec - close price
About

Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)

Key Points

Leading Pharmaceutical company[1] Alkem is the fifth largest player in domestic formulation market with a market share of 3.9% as on March 31, 2022.
It has established its leadership position in acute therapy, with a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutrient segments.

  • Market Cap 64,628 Cr.
  • Current Price 5,409
  • High / Low 6,440 / 4,407
  • Stock P/E 29.9
  • Book Value 984
  • Dividend Yield 0.74 %
  • ROCE 18.4 %
  • ROE 18.1 %
  • Face Value 2.00

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 35.5%

Cons

  • Promoter holding has decreased over last quarter: -0.72%
  • The company has delivered a poor sales growth of 11.3% over past five years.
  • Tax rate seems low

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
2,364 2,181 2,006 2,058 2,461 2,297 2,238 2,253 2,635 2,495 2,365 2,500 2,872
1,776 1,709 1,807 1,875 2,056 1,841 1,906 1,919 1,980 1,925 1,958 1,879 2,144
Operating Profit 588 472 200 183 406 456 332 334 655 569 408 621 728
OPM % 25% 22% 10% 9% 16% 20% 15% 15% 25% 23% 17% 25% 25%
43 63 54 55 74 61 77 65 62 44 71 106 120
Interest 8 7 13 22 20 23 22 21 19 21 21 21 18
Depreciation 54 58 55 57 58 58 57 58 59 58 69 64 63
Profit before tax 569 470 186 160 402 436 330 319 639 534 389 641 768
Tax % 2% 7% 59% 12% 13% 11% 23% 15% -1% 6% 16% 9% 9%
558 437 77 140 351 389 255 271 647 504 325 583 698
EPS in Rs 46.67 36.56 6.43 11.72 29.33 32.53 21.31 22.70 54.07 42.17 27.18 48.78 58.34
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
2,291 2,660 3,072 3,911 4,548 5,281 5,714 6,677 7,220 8,830 9,055 9,748 10,232
1,860 2,261 2,722 3,180 3,668 4,308 4,667 5,209 5,268 7,018 7,665 7,780 7,907
Operating Profit 432 399 350 731 880 973 1,048 1,468 1,951 1,812 1,389 1,968 2,325
OPM % 19% 15% 11% 19% 19% 18% 18% 22% 27% 21% 15% 20% 23%
166 164 177 240 115 101 66 96 175 199 254 239 342
Interest 79 84 73 59 24 32 28 39 43 38 86 82 81
Depreciation 36 43 60 74 76 108 141 187 199 219 230 244 254
Profit before tax 482 436 395 839 894 934 944 1,338 1,884 1,753 1,327 1,881 2,332
Tax % 3% -1% 7% 17% 1% 23% 15% 6% 11% 12% 15% 7%
467 440 368 700 883 716 800 1,264 1,685 1,541 1,134 1,747 2,110
EPS in Rs 390.40 368.17 30.75 58.56 73.86 59.87 66.90 105.75 140.93 128.90 94.88 146.13 176.47
Dividend Payout % 5% 5% 13% 22% 20% 22% 24% 24% 21% 26% 53% 27%
Compounded Sales Growth
10 Years: 14%
5 Years: 11%
3 Years: 11%
TTM: 9%
Compounded Profit Growth
10 Years: 15%
5 Years: 18%
3 Years: 3%
TTM: 38%
Stock Price CAGR
10 Years: %
5 Years: 22%
3 Years: 16%
1 Year: 7%
Return on Equity
10 Years: 18%
5 Years: 19%
3 Years: 17%
Last Year: 18%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 12 12 24 24 24 24 24 24 24 24 24 24 24
Reserves 2,291 2,703 3,077 3,576 4,369 4,861 5,441 6,257 7,602 8,720 9,326 10,531 11,747
1,229 947 1,103 380 368 548 503 1,209 1,384 2,294 1,182 1,005 619
479 540 657 843 1,137 1,381 1,324 1,616 1,763 2,132 2,200 2,478 2,736
Total Liabilities 4,011 4,202 4,861 4,822 5,898 6,814 7,292 9,106 10,773 13,169 12,731 14,038 15,125
832 909 870 875 1,126 1,471 1,606 1,837 1,758 1,882 1,825 1,782 1,661
CWIP 0 0 96 147 218 299 382 314 323 232 229 91 66
Investments 579 940 1,071 1,158 1,518 1,544 1,696 1,956 2,152 2,529 3,006 2,829 3,683
2,600 2,352 2,824 2,644 3,037 3,500 3,609 4,999 6,539 8,526 7,672 9,336 9,715
Total Assets 4,011 4,202 4,861 4,822 5,898 6,814 7,292 9,106 10,773 13,169 12,731 14,038 15,125

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
97 264 242 630 499 318 745 682 1,324 1,299 1,437 1,687
-349 119 -260 311 -362 -273 -313 -995 -1,121 -1,669 197 -866
274 -395 26 -958 -125 -60 -276 173 -209 437 -1,711 -959
Net Cash Flow 21 -12 8 -17 13 -15 156 -141 -5 67 -77 -138

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 46 40 45 45 51 60 62 85 79 73 71 66
Inventory Days 183 161 143 139 175 180 159 156 207 202 164 177
Days Payable 103 88 90 110 139 144 121 116 131 114 103 151
Cash Conversion Cycle 127 113 97 74 86 97 100 125 155 162 133 92
Working Capital Days 90 68 63 45 59 81 82 105 113 106 96 176
ROCE % 18% 15% 11% 22% 21% 19% 17% 20% 23% 18% 13% 18%

Shareholding Pattern

Numbers in percentages

Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
57.13% 57.13% 57.14% 57.16% 57.16% 57.16% 57.16% 56.74% 56.74% 56.74% 56.38% 55.66%
5.40% 5.41% 5.67% 4.46% 4.41% 4.44% 5.63% 6.03% 8.49% 9.11% 8.69% 9.02%
13.94% 14.14% 14.10% 15.73% 16.44% 16.69% 16.34% 17.63% 15.91% 15.63% 18.56% 19.21%
23.53% 23.32% 23.09% 22.65% 21.99% 21.69% 20.85% 19.58% 18.86% 18.51% 16.37% 16.12%
No. of Shareholders 86,88181,86984,10479,72176,51673,44066,79069,44265,18465,83069,62774,744

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls